Coherus Oncology, Inc. (CHRS)
$1.07+0.00%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $131M
- Beta
- 0.99
- P/E (TTM)
- -1.01
- Short % float
- 20.13%
- Days to cover
- 12.5
- SI change
- +2.1%
- 1W
- -7.76%
- 1M
- -20.15%
- vs SPY 1W
- -8.92%
- vs SPY 1M
- -23.14%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on CHRS?
- LOPJLB’s latest quantitative signal on Coherus Oncology, Inc. (CHRS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CHRS in?
- Coherus Oncology, Inc. (CHRS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Coherus Oncology, Inc. (CHRS) do?
- Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed …